文献速递肿瘤 PET/CT

恶性胸膜间皮瘤免疫治疗失败后贝伐珠单抗联合化疗在FDG PET上显示显著形态代谢反应

Dramatic Morphometabolic Response to Bevacizumab-Based Chemotherapy After Immunotherapy Failure in Malignant Pleural Mesothelioma on FDG PET.
PubMed 文献 · Clin Nucl Med · 2026-04-16

本文报告一例上皮型恶性胸膜间皮瘤患者,对伊匹木单抗联合纳武利尤单抗表现为原发性耐药,改用贝伐珠单抗联合培美曲塞加卡铂后,18F-FDG PET/CT显示显著的代谢反应。

要点

  • 上皮型恶性胸膜间皮瘤对伊匹木单抗联合纳武利尤单抗表现为原发性耐药。
  • 改用贝伐珠单抗联合培美曲塞加卡铂后,18F-FDG PET/CT显示显著的代谢反应。
  • 恶性胸膜间皮瘤中免疫导向治疗的作用日益受到重视。

核心结论

  • 一例上皮型恶性胸膜间皮瘤对伊匹木单抗联合纳武利尤单抗原发性耐药后,改用贝伐珠单抗联合培美曲塞加卡铂,18F-FDG PET/CT显示显著的代谢反应。

研究设计与样本

  • 病例报告:一例上皮型恶性胸膜间皮瘤患者。

主要发现

  • 该患者对伊匹木单抗联合纳武利尤单抗表现为原发性耐药。
  • 改用贝伐珠单抗联合培美曲塞加卡铂后,18F-FDG PET/CT显示显著的代谢反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Malignant mesothelioma is a rare but highly aggressive malignancy associated with a poor prognosis. Similar to many other solid tumors, cytotoxic chemotherapy has traditionally been the standard treatment for patients with locally advanced or metastatic malignant pleural mesothelioma (MPM). However, with increasing recognition of immune dysregulation, immune-directed therapies have assumed a growing role in the management of mesothelioma. Here, we report a case of epithelioid-type malignant pleural mesothelioma that demonstrated primary resistance to ipilimumab plus nivolumab, followed by a marked metabolic response on 18F-FDG PET/CT after switching to bevacizumab plus pemetrexed plus carboplatin.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Oksuzoglu K, Perktas L, Onner H, et al. Dramatic Morphometabolic Response to Bevacizumab-Based Chemotherapy After Immunotherapy Failure in Malignant Pleural Mesothelioma on FDG PET. Clin Nucl Med. 2026. PMID: 42080609. doi:10.1097/RLU.0000000000006495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。